ORCHID CELLMARK INC

CIK:0001107216|SEC Filings

Comprehensive Loss	9 Months Ended
Sep. 30, 2011
Comprehensive Loss [Abstract]
Comprehensive Loss	(11) Comprehensive Loss Comprehensive income is comprised of net earnings, foreign currency translation adjustments, and unrealized gains and losses on available-for-sale securities. Total comprehensive loss for the three months ended September 30, 2011 and 2010 was $1.9 million and $257 thousand, respectively, and total comprehensive loss for the nine months ended September 30, 2011 and 2010 was $6.0 million and $4.2 million, respectively. The difference from net loss for the three and nine months ended September 30, 2011 and 2010 consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale securities. Accumulated other comprehensive loss as reflected in the Consolidated Statement of Stockholders’ Equity and Comprehensive Income (Loss) includes cumulative foreign currency translation adjustments of $175 thousand and unrealized gain on available-for-sale securities of $1 thousand.

Comprehensive Loss

9 Months Ended

Sep. 30, 2011

(11) Comprehensive Loss

Comprehensive income is comprised of net earnings, foreign currency translation adjustments, and unrealized gains and losses on available-for-sale securities. Total comprehensive loss for the three months ended September 30, 2011 and 2010 was $1.9 million and $257 thousand, respectively, and total comprehensive loss for the nine months ended September 30, 2011 and 2010 was $6.0 million and $4.2 million, respectively. The difference from net loss for the three and nine months ended September 30, 2011 and 2010 consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale securities. Accumulated other comprehensive loss as reflected in the Consolidated Statement of Stockholders’ Equity and Comprehensive Income (Loss) includes cumulative foreign currency translation adjustments of $175 thousand and unrealized gain on available-for-sale securities of $1 thousand.

Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash flows from operating activities:
Net loss	$ (6,208)	$ (4,285)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense	482	792
Depreciation and amortization	2,693	2,777
Provision for losses on accounts receivable	67	36
Gain on sale of assets	4	22
Changes in assets and liabilities, net of effect of acquisition:
Accounts receivable	(1,668)	(1,419)
Inventory	(170)	(269)
Prepaids and other assets	232	(161)
Accounts payable	752	396
Accrued expenses and other current liabilities, including restructuring	254	2,995
Deferred revenue	(34)	213
Income taxes payable	(467)	1,252
Other liabilities	(42)	21
Net cash (used in) provided by operating activities	(4,105)	2,370
Cash flows from investing activities:
Purchases of available-for-sale securities		(9,404)
Maturities of available-for-sale securities	3,410	3,887
Capital expenditures	(2,025)	(2,096)
Net cash provided by (used in) investing activities	1,385	(7,613)
Cash flows from financing activities:
Proceeds from issuance of common stock	74
Net cash provided by financing activities	74
Effect of foreign currency translation on cash and cash equivalents	17	1,142
Net decrease in cash and cash equivalents	(2,629)	(4,101)
Cash and cash equivalents at beginning of period	8,107	8,600
Cash and cash equivalents at end of period	$ 5,478	$ 4,499

Consolidated Balance Sheets (USD $) In Thousands	Sep. 30, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 5,478	$ 8,107
Available-for-sale securities	8,468	11,714
Accounts receivable, net	11,341	9,781
Inventory	2,006	1,836
Prepaids and other current assets	983	1,213
Total current assets	28,276	32,651
Fixed assets, net	6,223	5,791
Goodwill	9,405	9,396
Other intangibles, net	2,824	3,901
Other assets	771	774
Total assets	47,499	52,513
Current liabilities:
Accounts payable	4,033	3,282
Accrued expenses and other current liabilities	5,985	6,198
Deferred revenue	980	1,014
Total current liabilities	10,998	10,494
Other liabilities	174	216
Total liabilities	11,172	10,710
Commitments and contingencies
Stockholders' equity:
Common stock; $0.001 per share par value; authorized 150,000,000 shares; issued 30,143,043 at September 30, 2011 and 30,098,269 at December 31, 2010	30	30
Additional paid-in capital	374,420	373,860
Accumulated other comprehensive income	208	36
Treasury stock at cost, 163,259 common shares at September 30, 2011 and December 31, 2010	(1,587)	(1,587)
Accumulated deficit	(336,744)	(330,536)
Total stockholders' equity	36,327	41,803
Total liabilities and stockholders' equity	47,499	52,513
Series A redeemable convertible preferred stock
Stockholders' equity:
Preferred stock value
Series A junior participating preferred stock
Stockholders' equity:
Preferred stock value